Clinical trials
Completed Muscular Dystrophies trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 6 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2021 | 1 |
| 2022 | 6 |
| 2023 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 60 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cooperative International Neuromuscular Research Group | 6 |
| GlaxoSmithKline | 3 |
| Nationwide Children's Hospital | 3 |
| University of Washington | 3 |
| Avidity Biosciences, Inc. | 2 |
| Catabasis Pharmaceuticals | 2 |
| Cedars-Sinai Medical Center | 2 |
| Edgewise Therapeutics, Inc. | 2 |
| Jerry R. Mendell | 2 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Muscular Dystrophies | 60 |
| Muscular Dystrophy, Duchenne | 28 |
| Neuromuscular Diseases | 13 |
| Musculoskeletal Diseases | 10 |
| Muscular Diseases | 9 |
| Genetic Diseases, Inborn | 7 |
| Nervous System Diseases | 7 |
| Spinal Cord Injuries | 7 |
| Muscular Disorders, Atrophic | 6 |
| Muscular Dystrophies, Limb-Girdle | 6 |
Trials
Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.